Nerandomilast

Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) [1][2].

Product Specifications

CAS Number

[1423719-30-5]

Product Name Alternative

BI 1015550

UNSPSC

12352005

Hazard Statement

H302, H361, H372

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Neurological Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nerandomilast.html

Purity

99.93

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=[S@]1C2=C(CC1)N=C(N3CCC(CC3)C4=NC=C(C=N4)Cl)N=C2NC5(CO)CCC5

Molecular Formula

C20H25ClN6O2S

Molecular Weight

448.97

Precautions

H302, H361, H372

References & Citations

[1]Pouzet P A, et al. Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma. United States. US9150586.|[2]Herrmann FE, et al. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Apr 20;13:838449.